The American company Moderna announced that it would file applications for conditional authorizations for its Covid-19 vaccine in the United States and Europe on Monday, after full results confirmed a high efficacy estimated at 94.1%.
Read also: Moderna: Stéphane Bancel, this Frenchman who is revolutionizing vaccines
Two weeks after announcing 94.5% efficacy based on preliminary results, Moderna reported that out of 196 participants in its large clinical trial who fell ill with Covid-19, 185 were in the placebo group and 11 in the vaccinated group. , or a calculated efficiency of 94.1%. No severe form of the disease appeared among the group of vaccinated participants.
